Department of Organic Chemistry, University Semmelweis H-1092 Budapest, Hogyes Endre u. 7, Hungary.
Curr Med Chem. 2013;20(1):95-107.
Drug repositioning, an innovative therapeutic application of an old drug, has received much attention as a particularly costeffective strategy in drug R&D Recent work has indicated that repositioning can be promoted by utilizing a wide range of information sources, including medicinal chemical, target, mechanism, main and side-effect-related information, and also bibliometric and taxonomical fingerprints, signatures and knowledge bases. This article describes the adaptation of a conceptually novel, more efficient approach for the identification of new possible therapeutic applications of approved drugs and drug candidates, based on a kernel-based data fusion method. This strategy includes (1) the potentially multiple representation of information sources, (2) the automated weighting and statistically optimal combination of information sources, and (3) the automated weighting of parts of the query compounds. The performance was systematically evaluated by using Anatomical Therapeutic Chemical Classification System classes in a cross-validation framework. The results confirmed that kernel-based data fusion can integrate heterogeneous information sources significantly better than standard rank-based fusion can, and this method provides a unique solution for repositioning; it can also be utilized for de novo drug discovery. The advantages of kernel-based data fusion are illustrated with examples and open problems that are particularly relevant for pharmaceutical applications.
药物重定位是一种将老药应用于新治疗领域的创新治疗策略,作为一种特别具有成本效益的药物研发策略受到了广泛关注。最近的研究表明,可以利用多种信息源(包括药物化学、靶点、作用机制、主要和副作用相关信息,以及生物计量学和分类学特征、签名和知识库)来促进药物重定位。本文描述了一种基于核的新型、更高效的数据融合方法,用于识别已批准药物和候选药物的新的潜在治疗应用。该策略包括:(1)信息源的潜在多表示;(2)信息源的自动加权和统计最优组合;(3)查询化合物部分的自动加权。通过在交叉验证框架中使用解剖治疗化学分类系统类别对性能进行了系统评估。结果证实,基于核的数据融合可以比标准的基于排序的融合更好地整合异构信息源,并且该方法为药物重定位提供了独特的解决方案;它还可以用于从头发现新药。通过示例和与药物应用特别相关的开放性问题说明了基于核的数据融合的优势。